Nymox gains patent for saliva cholesterol test:
This article was originally published in Clinica
Nymox Pharmaceutical has received notice of issuance of a US patent covering its method and device for using saliva to determine cholesterol levels. The patent augments the firm's existing diagnostic platform technology pipeline, said the company, which uses its proprietary test technology in two products for determining tobacco exposure or use, NicAlert, a saliva/urine test, and TobacAlert, a urine test. The Maywood, New Jersey firm also makes AlzheimAlert, a urine test to help physicians diagnose Alzheimer's disease.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.